Vomiting on Zepbound (tirzepatide): Incidence, Severity, and Realistic Expectations

How common is vomiting on Zepbound?

The figures come from the label's pooled analysis of two randomized, double-blind, placebo-controlled trials: 2,519 adults with obesity or overweight treated with Zepbound and 958 given placebo, with treatment lasting up to 72 weeks plus a 4-week off-drug follow-up; about a quarter of the treated group had type 2 diabetes [1]. Vomiting was reported by 8% of the 630 people on 5 mg, 11% of the 948 on 10 mg and 13% of the 941 on 15 mg, compared with 2% of the 958 people on placebo [1]. It appears on the label's list of common adverse reactions, which covers reactions reported in at least 5% of treated patients [1].

The two trials behind that table are SURMOUNT-1, which enrolled 2,539 adults with obesity or overweight and no diabetes for 72 weeks [2], and SURMOUNT-2, which enrolled 938 adults with overweight or obesity and type 2 diabetes [3]. The label pools them, so the rates above describe the mixed population rather than people without diabetes alone [1].

The 2.5 mg starting dose is not in that table. The label's vomiting figures cover the three maintenance doses (5, 10 and 15 mg), while 2.5 mg is an initiation dose only [1].

How severe is it, and how often does it end treatment?

Severe gastrointestinal reactions of any kind (nausea, vomiting, diarrhea and the rest combined) were reported by 1.7% of people on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, versus 1% on placebo [1]. The label reports severe GI reactions as one combined category rather than separating vomiting out [1].

Across the same pooled trials, any gastrointestinal adverse reaction was reported by 56% of people on every Zepbound dose, against 30% on placebo [1]. Discontinuation for gastrointestinal reasons was 1.9% at 5 mg, 3.3% at 10 mg and 4.3% at 15 mg, against 0.5% on placebo [1]. Discontinuation for any adverse reaction at all was 4.8%, 6.3% and 6.7% at 5, 10 and 15 mg, against 3.4% on placebo, and the label says the majority of people who stopped because of an adverse reaction did so in the first few months because of gastrointestinal reactions [1].

Why does Zepbound cause vomiting?

Tirzepatide activates both the GIP and GLP-1 receptors, and the label states that tirzepatide delays gastric emptying, that the delay is largest after the first dose and that it diminishes over time [1]. The label does not establish exactly why vomiting occurs [1].

Does it fade with time?

The label describes the pattern in broad terms: the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1]. It ties the recommended step-by-step dose increase to reducing the risk of gastrointestinal adverse reactions [1].

The label does not give a week-by-week timeline for vomiting, so how long symptoms last at a given dose is not something it quantifies [1].

What the dosing schedule says

Zepbound starts at 2.5 mg once weekly for 4 weeks, which the label calls a treatment initiation dose and not an approved maintenance dose [1]. After 4 weeks the dose goes to 5 mg, and it can then be raised in 2.5 mg steps, but only after at least 4 weeks on the current dose [1]. Maintenance for weight reduction is 5, 10 or 15 mg once weekly, with 15 mg the maximum [1].

Vomiting was reported more often at higher maintenance doses: 8% at 5 mg, 11% at 10 mg and 13% at 15 mg [1]. The label says that if a maintenance dose is not tolerated, a lower maintenance dose can be considered [1].

What the label says to watch for

Kidney injury from fluid loss. The label describes postmarketing reports of acute kidney injury, some requiring hemodialysis, in people taking GLP-1 receptor agonists or Zepbound [1]. The majority of those events occurred in people who had gastrointestinal reactions leading to dehydration, such as nausea, vomiting or diarrhea [1]. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1].

Severe gastroparesis. Zepbound is not recommended in people with severe gastroparesis [1].

Pancreatitis. The label describes acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, in people taking GLP-1 receptor agonists or Zepbound [1]. The warning sign is persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting [1]. The label says to discontinue Zepbound if pancreatitis is suspected [1].

Gallbladder disease. Cholecystitis was reported in 0.7% of Zepbound-treated patients versus 0.2% on placebo, and cholelithiasis in 1.1% versus 1% [1]. The label notes these events were associated with weight reduction [1].

How this compares with semaglutide

SURPASS-2 compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes [4]. A separate trial, SURMOUNT-5, compared maximum tolerated doses of tirzepatide (10 or 15 mg) with semaglutide (1.7 or 2.4 mg) in adults with obesity without type 2 diabetes [5]. In SURPASS-2, a 40-week trial of 1,879 adults with type 2 diabetes on metformin, vomiting was reported by 6% to 10% of tirzepatide-treated participants, depending on dose, and by 8% of those on semaglutide 1 mg [4]. The semaglutide dose in SURPASS-2 (1 mg) is lower than the 1.7 or 2.4 mg used in SURMOUNT-5 [4][5].

The label cautions that adverse reaction rates from trials of one drug cannot be directly compared with rates from trials of another [1].